Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5715066 | 0.92 | SMN1; SMN2 (0.45) | SMN1; SMN2POLBKMT2AKDM4EALDH1A1 | |
| SCHEMBL5714923 | 0.92 | KMT2A (0.40) | POLBKMT2AKDM4EALDH1A1MGLL | |
| SCHEMBL5714500 | 0.91 | SMN1; SMN2 (0.43) | SMN1; SMN2POLBHDAC1MGLLNPC1 | |
| SCHEMBL5715380 | 0.89 | KDM4E (0.51) | SMN1; SMN2POLBKMT2AKDM4EALDH1A1 | |
| SCHEMBL5716251 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBKMT2AALDH1A1HDAC1 | |
| SCHEMBL5714513 | 0.85 | MAPT (0.38) | SMN1; SMN2POLBKMT2AALDH1A1NPC1 | |
| SCHEMBL5714454 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBKDM4EALDH1A1HDAC1 | |
| SCHEMBL5714712 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBKDM4EALDH1A1HDAC1 | |
| SCHEMBL5714995 | 0.83 | SIGMAR1 (0.42) | KMT2AALDH1A1MGLL | |
| SCHEMBL5714548 | 0.83 | KMT2A (0.41) | SMN1; SMN2KMT2AKDM4EALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | SMN1; SMN2 3125/4885POLB 2674/4885KMT2A 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.